A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Grants and Contracts Details

StatusFinished
Effective start/end date5/22/20 → 7/20/21

Funding

  • Parexel International LLC: $8,000.00